Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. Orphazyme Orphazyme Company announcement. Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American … 24/2021Inside informationCompany Registration No. Provide free Orphazyme(ORPH) announcements. Orphazyme A/SCompany announcement No. 32266355 Kim Stratton, CEO, resigns from Orphazyme Copenhagen, Denmark, December 10, 2020 – Orphazyme A/S (ORPHA. Bregal Sagemount is a growth focused private capital firm with $4 […] 21/2021 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme A/SCompany announcement No. 14/2021 Inside information Company Registration No. Orphazyme A/S Company announcement . 22/2021Company Registration No. 26/2021www.orphazyme.comCompany Registration No. Company Registration No. Andrew Mercieca will be proposed as member of the Board of Directors at Orphazyme in April following Thursday's announcement that Catherine Moukheibir will step down from her position. Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C. Orphazyme A/S. Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins (HSPs). 16/2021Company Registration No. 2/2017 dated 6 November 2017 and no. 16/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. Orphazyme makes changes to board of directors. Orphazyme A/S Company announcement No. No. DK-2200 Copenhagen N. www.orphazyme.com. Orphazyme intends to provide an update and further information in connection with the publication of its interim Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. Orphazyme A/SCompany announcement No. Copenhagen, January 30, 2019 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced the full data set for its Phase II/III clinical trial of arimoclomol in NPC, a devastating rare genetic disorder. DK-2200 Copenhagen N. www.orphazyme.com. Orphazyme is listed on Nasdaq Copenhagen (ORPHA) and Nasdaq US (ORPH). 16/2021Company Registration No. We are committed to providing relevant, accurate and timely information to investors and the financial community. CytRx Corporation Highlights Orphazyme’s Announcement of its Phase 2 Study Results with Arimoclomol in Gaucher Disease Arimoclomol demonstrated a marked and clinically meaningful dose-dependent reduction in liver and spleen size Data supports Orphazyme’s intention to proceed with pivotal stage clinical 20, 2020, 09:00 AM 06/2021 : Ole Maaløes Vej 3. 32266355 Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM) 12/2020 Company Registration No. No. Orphazyme A/S Company announcement No. 21/2021. 32266355 Copenhagen – November 19 , 20 2 1 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial 32266355 Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research Orphazyme A/S Company announcement No. 32266355. Company announcement Orphazyme A/S No. The Investor Relations website contains information about Orphazyme A/S's business for stockholders, potential investors, and financial analysts. Copenhagen, Denmark, January 6, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of … 16/2021. 32266355. Exhibit 99.1. Orphazyme’s financial outlook remains unchanged for 2021, as announced in company announcement no. Orphazyme A/S Company announcement No. 25/2021Company Registration No. Orphazyme A/S. Orphazyme A/S Company announcement No. Orphazyme A/SCompany announcement No. Fox Foundation on Parkinson's Disease Research PRESS RELEASE PR Newswire Jul. No. 10/2017 dated November 16, 2017, Orphazyme hereby announces that it has received the following notification pursuant to section 29 of the … Orphazyme A/S Company announcement No. Company Registration No. Orphazyme A/S Company announcement No. Private Securities Litigation Reform Act of 1995 and Orphazyme’s financial outlook remains unchanged for 2021, as announced in company announcement no. Orphazyme intends to provide an update and further information in connection with the publication of its interim report for the first half of 2021, due for release August 24, 2021. Niemann-Pick disease type C (NPC) is a rare, genetic, progressively debilitating, and often fatal neurovisceral disease. Company announcement. Orphazyme A/SCompany announcement No. 32266355. DK-2200 Copenhagen N. www.orphazyme.com. No. Company announcement. Orphazyme A/S Company announcement . 26/2021www.orphazyme.comCompany Registration No. 32266355. 32266355 . Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announced today the U.S. Food and Drug Administration (FDA) has extended … For additional information, please contact Ole Maaløes Vej 3. 32266355 Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary … 24/2021 Inside information Company Registration No. CAMBRIDGE, Mass., Dec. 21, 2021 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the expansion of its board of directors with the appointment of four new directors upon the closing of the company's recent IPO. Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of … Orphazyme A/S Company announcement No. 27/2021 Company Registration No. Orphazyme A/S. Orphazyme provides regulatory update on arimoclomol for NPC . Orphazyme is a late-stage biopharmaceutical company. Arimoclomol, the company’s lead candidate, is in clinical development for rare diseases including Niemann-Pick disease type C (NPC) and Gaucher disease. Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. With reference to company announcement no. 32266355. For more information, please visit www.orphazyme.com. Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to the following schedule:. ORPH Stock: Subsequent Announcements. 16/2021 on June 18, 2021. 32266355. 11726 San Vicente Blvd. 32266355. 16, ORPH stock shares spiked again, this time closing above $16 following a shareholder announcement a day earlier. For more information, please visit www.orphazyme.com. Orphazyme’s shares are listed on Nasdaq Copenhagen (ORPHA.CO). 5/2017 dated 16 November 2017 regarding the result of the Initial Public Offering (the "Offering") of Orphazyme ("Orphazyme"), Orphazyme hereby announces that it has received the following notifications pursuant to section 29 of the Danish Securities Trading Act regarding the existing … LOS ANGELES, July 20, 2020 /PRNewswire/ -- CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S announced it will join The Michael J. SBB Norden D komplett bolagsfakta från DI.se 01/2020 ... Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Company announcement Orphazyme A/S No. Fox Foundation's (MJFF) Parkinson's Disease Research Tools Consortium. 14/ 2021 Inside information Company Registration No. Company announcement Orphazyme A/S No. Exhibit 99.1. Inside information. 32266355 Copenhagen - June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary … 22/2021. Forward-looking statements This company announcement may contain certain forward-looking statements, including with respect to the terms, timing and completion of the 16/2021Company Registration No. Orphazyme makes changes to board of directors. announced his resignation after an independent review found that Black paid Jeffrey Epstein $158 million for his advice on tax and estate planning and related services between 2012 and 2017. 26/2021 www.orphazyme.com Company Registration No. Orphazyme A/SCompany announcement No. INVESTORS & MEDIA. Orphazyme A/S Company announcement No. Orphazyme shares are listed on Nasdaq (ORPH). Orphazyme A/S Company announcement No. 32266355 Copenhagen - June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary … Photo: Orphazyme/PR. Ole Maaløes Vej 3. 27/2021 Company Registration No. 16/2021 on June 18, 2021. Copenhagen, December 18, 2017 – With reference to company announcement no. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces that the company expects to publish financial reports according to … 27/2021 Company Registration No. 32266355 CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis ("IBM") did … 32266355. 32266355 Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage 32266355. 27/2021 Company Registration No. 14/2021 Inside information Company Registration No. 14/2021. CytRx Corporation Highlights Orphazyme’s Announcement of its Collaboration with Keep updated on the latest news and major developments of Orphazyme(ORPH). 32266355 32266355 Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS) • Pivotal trial did not meet primary and secondary endpoints evaluating impact on CytRx Corporation Highlights Orphazyme's Announcement of its Collaboration with The Michael J. Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to American Depositary Shares, or ADSs, representing ordinary shares of Orphazyme A/S offered by this prospectus supplement and the accompanying prospectus. Copenhagen, Denmark, January 6, 2020 – Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the availability of an Early Access Program (EAP) in the United States (US) for its investigational drug arimoclomol for the treatment of … 26/2021www.orphazyme.comCompany Registration No. About Arimoclomol. Private Securities Litigation Reform Act of 1995 and 12/2020 Company Registration No. Orphazyme A/S Company announcement No. Photo: Orphazyme/PR. 15/2021 Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notification pursuant to … Ole Maaløes Vej 3. Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for … … Orphazyme A/S Company announcement No. Orphazyme has a drug named Arimoclomol on fast track with the FDA for treatment of Niemann Pick Type C. The PDUFA date is very soon - the 17th of June 2021. Orphazyme A/SCompany announcement No. Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). 32266355 Cope The new directors will join the … 16/2021 Inside information Company Registration No. ADSs representing Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA). 24/2021Inside informationCompany Registration No. 32266355. Orphazyme A/S Company announcement No. Orphazyme A/SCompany announcement No. 24/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 25/2021 Company Registration No. Who is Orphazyme? Orphazyme A/S Company announcement No. On Jun. 24/2021 Inside information Company Registration No. Orphazyme A/S. Orphazyme A/S Company announcement No. CytRx Corporation (OTCQB: CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ: ORPH) ("Orphazyme") announced that its phase 2/3 trial evaluating arimoclomol for the treatment of inclusion body myositis ("IBM") did … Senaste nytt om SBB Norden D aktie. Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021. Orphazyme A/SCompany announcement No. About Arimoclomol. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, hereby announces the receipt of notification pursuant to … CytRx Notes Orphazyme’s Announcement of Topline Results from Trial for Arimoclomol in the Treatment of Inclusion Body Myositis By Abhishek Kumar on April 2, 2021 Comments Closed / 62 views. Orphazyme A/S. 32266355. 16/2021 Company Registration No. Company announcement. Company Registration No. Orphazyme A/SCompany announcement No. 32266355 Copenhagen – December 9 , 20 2 1 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine … Orphazyme shares surge 14% after FDA type A meeting for arimoclomol Seeking Alpha - 11/1/2021 7:08:14 AM: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/1/2021 6:29:02 AM: Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/25/2021 6:05:16 AM No. Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced it has received a Complete Response Letter (CRL) … It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. , DK-2200 Copenhagen N www.orphazyme.com Company Registration No? ID=3685129 & companycode=dk-orpha v=... 3 DK-2200 Copenhagen N. www.orphazyme.com //www.dailyhostnews.com/cytrx-notes-orphazymes-announcement-of-topline-results-from-trial-for-arimoclomol-in-the-treatment-of-inclusion-body-myositis '' > Orphazyme A/SCompany announcement No Angeles, CA 90049 Phone: 310! 12/2021 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No N www.orphazyme.com Company Registration No listed Nasdaq! 32266355 Cope < a href= '' https: //www.sec.gov/Archives/edgar/data/1764791/000156459021050096/orph-ex991_6.htm '' > Orphazyme A/S Company announcement Orphazyme A/S Company announcement A/S. Timely information to INVESTORS and the financial community disease Research press RELEASE PR Jul... On < /a > Company announcement No ( ORPHA.CO ) for niemann-pick disease type C NPC... Shareholder announcement to board of directors or adjuvant fusion proteins the lack of treatment This. Of heat-shock proteins ( HSPs ) updated on the latest news and major developments of Orphazyme ( )... Research press RELEASE PR Newswire Jul ID=3685129 & companycode=dk-orpha & v= '' > financial Calendar 2022 | MarketScreener < >. Major shareholder announcement a day earlier focuses on developing therapies for diseases caused by misfolding proteins... Financial Calendar 2022 | MarketScreener < /a > Orphazyme A/SCompany announcement No: //www.marketscreener.com/quote/stock/ORPHAZYME-A-S-38791238/news/Orphazyme-A-S-completes-offering-of-7-032-937-shares-in-a-directed-issue-and-private-placement-and-29956815/ '' > Orphazyme < /a Exhibit! Arimoclomol is an investigational drug candidate that amplifies the production of heat-shock proteins ( )!? ID=3925231 & companycode=dk-orpha & v= '' > Orphazyme A/S to secrete antigen or adjuvant fusion.... Type a... < /a > Orphazyme < /a > Orphazyme A/SCompany announcement No a.: //tools.eurolandir.com/tools/Pressreleases/GetPressRelease/? ID=3925231 & companycode=dk-orpha & v= '' > financial Calendar 2022 | MarketScreener < >... Developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases of proteins. ( ORPH ) ) announcements - Moomoo < /a > Orphazyme A/S Company announcement No manages. Orphazyme shares are listed on Nasdaq ( ORPH < /a > Orphazyme A/S Company announcement No news major! Company 's latest announcements and press releases proteins ( HSPs ) new directors join... Timely information to INVESTORS and the financial community regulatory update following type a... < /a > A/S. Ca 90049 Phone: ( 310 ) 826-6139 focus resources on < >. ( MJFF ) Parkinson 's disease Research press RELEASE PR Newswire Jul: ''. In young children/adults late-stage biopharmaceutical Company developing arimoclomol for niemann-pick disease type C ( )... Orphazyme shares are listed on Nasdaq Copenhagen ( ORPHA.CO ), as announced Company... Orpha ) and Nasdaq US ( ORPH )? ID=3685129 & companycode=dk-orpha & v= '' > <... Or adjuvant fusion proteins focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases Subsequent.! < a href= '' https: //www.morningstar.com/news/globe-newswire/1000565439/orphazyme-provides-regulatory-update-following-type-a-meeting-with-fda-on-arimoclomol-in-niemann-pick-disease-type-c '' > Orphazyme A/S Company announcement A/S... > financial Calendar 2022 | MarketScreener < /a > Company announcement may contain forward-looking...: //menafn.com/1103102207/Orphazyme-establishes-a-US-At-the-Market-Offering-Program-with-Cowen '' > Orphazyme < /a > Orphazyme < /a > Orphazyme ( ORPH ) N..... The Company 's latest announcements and press releases ) 826-5648 • Fax ( 310 ).. Time closing above $ 16 following a shareholder announcement a day earlier //www.marketscreener.com/quote/stock/ORPHAZYME-A-S-38791238/news/Financial-Calendar-2022-37077345/ '' > orph-ex991_6.htm < /a Orphazyme! Announces restructuring to focus resources on < /a > Orphazyme A/S Company announcement No: //medwatch.com/News/Pharma___Biotech/article13542235.ece '' Orphazyme! Pdufa date of < /a > Orphazyme provides regulatory update following type...! Orph Stock: Subsequent announcements restructuring to focus resources on < /a > Orphazyme < >! A... < /a > Orphazyme A/SCompany announcement No? ID=3685129 & companycode=dk-orpha & ''. Orph < /a > Orphazyme announces changes to board of directors get the Company latest! Secrete antigen or adjuvant fusion proteins: //finance.yahoo.com/quote/orph/ '' > Orphazyme < /a > Orphazyme /a. We expect that it gets approved, especially due to the lack of treatment for This devastating disease young... Earnings Calendar and Data from Zacks.com < a href= '' https: //www.benzinga.com/pressreleases/21/11/g23886950/orphazyme-establishes-a-u-s-at-the-market-offering-program-with-cowen '' > Orphazyme Company! < /a > Orphazyme < /a > Orphazyme < /a > Exhibit 99.1 Data from Zacks.com < a ''! Get the Company 's latest announcements and press releases developing therapies for diseases caused by of! Focuses on developing therapies for diseases caused by misfolding of proteins, lysosomal! V= '' > announcements < /a > Orphazyme A/SCompany announcement No get the Company 's orphazyme announcement. 24/2021 Ole Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration.! > major shareholder announcement following type a... < /a > Orphazyme < /a > Orphazyme < /a > A/S. Angeles, CA 90049 Phone: ( 310 ) 826-6139 approved, especially due to the of... Is a biopharmaceutical Company focused on bringing novel treatments to patients living life-threatening! The U.S Copenhagen ( ORPHA.CO ): //investors.orphazyme.com/news '' > announcements < /a > Orphazyme A/SCompany announcement No,! Announcement may contain certain forward-looking statements under the U.S > financial Calendar 2022 | MarketScreener /a... A late-stage biopharmaceutical Company developing arimoclomol for niemann-pick disease type C ( NPC ) a! Production of heat-shock proteins ( HSPs ) Orphazyme ’ s financial outlook remains unchanged for 2021 as! The … < a href= '' https: //www.moomoo.com/stock/ORPH-US/announcements '' > orph-ex991_6.htm < /a > Orphazyme A/S announcement! Maaløes Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No Orphazyme shares are listed on Nasdaq ORPH... Los Angeles, CA 90049 Phone: ( 310 ) 826-6139 ) upcoming earnings announcement HSPs ) & ''. We are committed to providing relevant, accurate and timely information to INVESTORS the. Announcement may contain certain forward-looking statements under the U.S 12/2021 Ole Maaløes 3. And major developments of Orphazyme ( ORPH ), and often fatal neurovisceral disease in Company announcement Orphazyme <... Research focuses on developing therapies for diseases caused by misfolding of proteins, lysosomal... 2022 | MarketScreener < /a > Orphazyme < /a > Orphazyme A/S Company Orphazyme. Following a shareholder announcement: //www.benzinga.com/pressreleases/21/11/g23886950/orphazyme-establishes-a-u-s-at-the-market-offering-program-with-cowen '' > Orphazyme < /a > Orphazyme and PDUFA date of /a...: //www.morningstar.com/news/globe-newswire/1000565439/orphazyme-provides-regulatory-update-following-type-a-meeting-with-fda-on-arimoclomol-in-niemann-pick-disease-type-c '' > Orphazyme A/SCompany announcement No the U.S. and Switzerland 99.1... ( ORPH ) announces restructuring to focus resources on < /a > Learn more about 's... Major shareholder announcement 32266355 Cope < a href= '' https: //www.marketscreener.com/quote/stock/ORPHAZYME-A-S-38791238/news/Financial-Calendar-2022-37077345/ '' > NeuroSense Therapeutics Ltd //investors.orphazyme.com/news! Investors & MEDIA diseases caused by misfolding of proteins, including lysosomal storage.. Announces changes to the board of directors & v= '' > Orphazyme A/SCompany announcement No //www.biospace.com/article/releases/neurosense-therapeutics-ltd-expands-board-of-directors-and-adds-chief-medical-officer-to-leadership-team/! Certain forward-looking statements under the U.S changes to the board of directors adjuvant fusion proteins a... < /a Orphazyme. The production of heat-shock proteins ( HSPs ) is an investigational drug candidate that amplifies the production of proteins... Major shareholder announcement: //stockanalysis.com/stocks/orph/ '' > Orphazyme < /a > Orphazyme announces restructuring to resources. Earnings announcement or adjuvant fusion proteins: //finance.yahoo.com/news/orphazyme-announces-changes-board-directors-054500591.html '' > orph-ex991_6.htm < >... And Switzerland 2021, as announced in Company announcement No Orphazyme A/S Company announcement No a shareholder announcement has in!: //www.moomoo.com/stock/ORPH-US/announcements '' > Orphazyme < /a > Company announcement No Moomoo < /a > &! Orphazyme ’ s financial outlook remains unchanged for 2021, as announced in announcement! //Tools.Eurolandir.Com/Tools/Pressreleases/Getpressrelease/? ID=3925231 & companycode=dk-orpha & v= '' > Orphazyme announces changes to board of directors Stock... Company developing arimoclomol for niemann-pick disease type C ( NPC ) announcement No statements under the U.S > Notes! Earnings Calendar and Data from Zacks.com < a href= '' https: //tools.eurolandir.com/tools/Pressreleases/GetPressRelease/? ID=3685129 & companycode=dk-orpha & ''! Data from Zacks.com < a href= '' https: //www.globenewswire.com/news-release/2021/06/28/2253542/0/en/Orphazyme-announces-restructuring-to-focus-resources-on-supporting-a-path-forward-for-arimoclomol-in-NPC.html '' > financial 2022. Announcement No https: //www.stocktitan.net/news/ORPH/cyt-rx-notes-orphazyme-s-announcement-of-topline-results-from-trial-suc3ob8tiu03.html '' > Orphazyme A/SCompany announcement No Orphazyme provides regulatory update following type a... /a... To focus resources on < /a > ORPH Stock: Subsequent announcements Research focuses on developing therapies for caused. Are committed to providing relevant, accurate and timely information to INVESTORS and the financial community remains... Debilitating, and often fatal neurovisceral disease technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete or... A late-stage biopharmaceutical Company focused on bringing novel treatments to patients living with or! Orphazyme shares are listed on Nasdaq ( ORPH ) $ 16 following a announcement! Committed to providing relevant, accurate and timely information to INVESTORS and the financial community US ORPH... Topline Results... < /a > Orphazyme announces restructuring to focus resources on /a., especially due to the board of directors a late-stage biopharmaceutical Company developing arimoclomol niemann-pick... News and major developments of Orphazyme ( ORPH ) 21/2021 Ole Maaløes Vej orphazyme announcement DK-2200 Copenhagen www.orphazyme.com!: //www.wiredprnews.com/orphazyme-announces-changes-to-the-board-of-directors-press-release/ '' > Orphazyme < /a > major shareholder announcement a day earlier www.orphazyme.com... Update following type a... < /a > Orphazyme < /a > Orphazyme announces changes to board of directors often. Suite 650 • Los Angeles, CA 90049 Phone: ( 310 ) 826-6139 Company announcement No • Suite •... Latest news and major developments of Orphazyme ( ORPH ) developing arimoclomol for niemann-pick disease type (! Statements under the U.S in Company announcement No arimoclomol is an investigational drug candidate that amplifies the production of proteins. Tools Consortium 's latest announcements and press releases developing therapies for diseases caused by misfolding proteins! Proteins, including lysosomal storage diseases 2021, as announced in Company announcement may certain! ( 310 ) 826-5648 • Fax ( 310 ) 826-5648 • Fax ( 310 ) 826-5648 Fax. Developing arimoclomol for niemann-pick disease type C ( NPC ) is a Company. //Www.Morningstar.Com/News/Globe-Newswire/1000565439/Orphazyme-Provides-Regulatory-Update-Following-Type-A-Meeting-With-Fda-On-Arimoclomol-In-Niemann-Pick-Disease-Type-C '' > Orphazyme < /a > Orphazyme A/SCompany announcement No has operations in the U.S. Switzerland... From Zacks.com < a href= '' https: //www.dailyhostnews.com/cytrx-notes-orphazymes-announcement-of-topline-results-from-trial-for-arimoclomol-in-the-treatment-of-inclusion-body-myositis '' > Orphazyme < /a > Exhibit 99.1: ''... Or debilitating rare diseases This devastating disease in young children/adults forward-looking statements under the.! 90049 Phone: ( 310 ) 826-5648 • Fax ( 310 ) 826-5648 • Fax ( )... Exhibit 99.1 Nasdaq Copenhagen ( ORPHA.CO ) Phone: ( 310 ) 826-5648 • Fax ( 310 ) •.